Perbak Capital Partners LLP Invests $347,000 in Omnicell, Inc. $OMCL

Key Points

• Perbak Capital Partners LLP has acquired a new stake in Omnicell, Inc., purchasing 9,922 shares valued at approximately $347,000 during the first quarter.
• Omnicell reported earnings of $0.45 per share for the latest quarter, exceeding analysts' estimates, with quarterly revenue reaching $290.56 million.
• Analysts have mixed ratings on Omnicell, with some raising target prices while others have lowered them, resulting in an average rating of "Moderate Buy" and a price target of $46.71.

Perbak Capital Partners LLP acquired a new stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) in the first quarter, according to its most recent disclosure with the SEC. The firm acquired 9,922 shares of the company's stock, valued at approximately $347,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Lazard Asset Management LLC boosted its position in shares of Omnicell by 81.6% during the fourth quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company's stock valued at $73,093,000 after buying an additional 737,536 shares during the period. Toronto Dominion Bank purchased a new stake in shares of Omnicell during the fourth quarter worth approximately $30,637,000. Pacer Advisors Inc. acquired a new position in Omnicell in the 1st quarter valued at $10,542,000. Nuveen LLC purchased a new position in Omnicell in the 1st quarter valued at $6,218,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in Omnicell during the 4th quarter worth $7,795,000. Hedge funds and other institutional investors own 97.70% of the company's stock.

Omnicell Trading Down 3.0%

Shares of Omnicell stock traded down $1.01 on Friday, reaching $32.11. The company had a trading volume of 423,987 shares, compared to its average volume of 540,095. The firm's 50 day moving average price is $30.44 and its two-hundred day moving average price is $31.37. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.24 and a current ratio of 1.42. Omnicell, Inc. has a 52-week low of $22.66 and a 52-week high of $55.74. The firm has a market cap of $1.47 billion, a PE ratio of 64.22, a PEG ratio of 7.23 and a beta of 0.82.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.30 by $0.15. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The firm had revenue of $290.56 million during the quarter, compared to the consensus estimate of $275.57 million. During the same quarter last year, the firm earned $0.51 EPS. The firm's revenue for the quarter was up 5.0% on a year-over-year basis. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. Sell-side analysts predict that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

OMCL has been the subject of a number of recent research reports. Piper Sandler cut their price objective on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a report on Monday, August 11th. Wall Street Zen downgraded Omnicell from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th. Wells Fargo & Company upped their target price on Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a report on Monday, July 21st. Finally, Bank of America raised their target price on Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research note on Friday, May 23rd. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $46.71.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.